# A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

> **NCT01470599** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 150 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** CP-690,550
- **DRUG:** CP-690,550

## Key facts

- **NCT ID:** NCT01470599
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470599, "A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01470599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*